ArticleFish physiology and biochemistry2025
Analysis of the efficacy of two molecular adjuvants, flagellin and IFN-γ, on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus).
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aquaculture industry frequently encounters disease outbreaks, high mortalities, as well as emergence of new pathogens due to its intensification. Streptococcus agalactiae (Lancefield's group B Streptococcus) is an important pathogen extensively causing infectious disease in tilapia resulting in huge economic loss and mortality. To date, vaccination has proved to be successful in defending against infectious diseases prevailing among farmed fish species. This study aimed to develop an S. agalactiae inactivated vaccine (SAIV) using molecular adjuvants, flagellin and tilapia interferon gamma (IFN-γ), and to assess the generated immune response and protective efficacy of the adjuvant incorporated vaccine against S. agalactiae infection in Nile tilapia. The fish were vaccinated with SAIV together with either flagellin or IFN-γ and both together by intraperitoneal injection. The vaccinated fish were challenged with a virulent strain of S. agalactiae on day 36 and monitored for 3 weeks to assess cumulative mortality. The results showed that the vaccine offered significant protection with relative percentage survival (RPS) of 59.37%, 71.87%, and 81.25% observed for bacterin vaccine adjuvanted with flagellin, IFN-γ and both, respectively, with an RPS of 15.62% for the unadjuvanted bacterin control group after challenge with S. agalactiae. The vaccine induced specific IgM antibodies against S. agalactiae in the vaccinated groups, and the antibody response was significantly increased following booster vaccination in the fishes administered with vaccine adjuvanted with flagellin, IFN-γ and both. Furthermore, after vaccination, MHC-II and IgM gene expression was found significantly upregulated in head kidney and spleen, in line with an elevated specific IgM titer. Innate immune parameters including catalase, lysozyme, superoxide dismutase, myeloperoxidase, and bactericidal activities were significantly increased in fishes immunized when compared with the unvaccinated controls (P < 0.05). Histopathological examinations of tissue sections of the head kidney, spleen, liver, kidney, gills, and brain were performed on vaccinated and non-vaccinated fish which showed mild infiltrations. In conclusion, flagellin and IFN-γ have shown potential for use as molecular adjuvants to enhance the efficacy of fish vaccines against S. agalactiae infections.
Indexed as
Identifiers
39937376What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.